Rexulti (Brexpiprazole) Rexulti (Brexpiprazole) is a unique medication with many indications. This medication was initially approved by the U.S. Food and Drug Administration (FDA) in July 2015 for Schizophrenia and treatment-resistant Major Depressive Disorder. This medication has an uncommon mechanism of action that makes it useful in treating difficult symptomatology. Rexulti is part of the atypical antipsychotic class of medications; it works as a serotonin-dopamine activi
Most people have heard the terms, “ADHD” and “ADD”, and these terms are often used jokingly to describe difficulties in getting things done. However, the experiences of people who have “attention-deficit-hyperactivity disorder” and “attention-deficit-disorder” (ADHD/ADD) rise above normal human struggles with focus. ADD/ADHD occurs when the concentration of two neurotransmitters: dopamine and norepinephrine are too low in the prefrontal cortex (the front part of the brain).